SAI Parenteral Limited Acquires 74.6% Stake in Australia’s Noumed Pharmaceuticals for Rs.125 Crore..

Varahi media.com online news,India,December 1, 2025: SAI Parenteral Limited (SPL), a diversified pharmaceutical formulations company, has acquired a 74.6% controlling stake in Adelaide-based Noumed Pharmaceuticals Pty Ltd for a total consideration of ₹125 crore.

The company had filed its Draft Red Herring Prospectus (DRHP) for an IPO with SEBI on September 30, 2025. The IPO, with a face value of ₹5 per equity share, comprises a fresh issue of up to ₹285 crore and an offer for sale of up to 3.5 million equity shares by existing shareholders.

Noumed Pharmaceuticals generates annual revenue of approximately AUD 60 million and is a leading supplier of private-label over-the-counter (OTC) medicines to major pharmacy chains across Australia and New Zealand.

The company is currently building a state-of-the-art manufacturing facility in Adelaide with an investment of AUD 53 million; the plant is scheduled to commence commercial operations in Q4 CY 2026. Noumed boasts a robust portfolio of over 451 registered product dossiers spanning multiple therapeutic categories.

Mr. Anil KK, Managing Director, SAI Parenteral Limited, commented: “This acquisition is a pivotal and transformative milestone in our journey to become a global, innovation-led formulations and CDMO platform.

By integrating Noumed’s R&D expertise, distribution network, extensive dossier library, and upcoming manufacturing facility with SAI Parenteral’s strengths in India, we are unlocking significant synergies across the entire value chain. This move accelerates our entry into semi-regulated and regulated markets with a broader and more competitive product portfolio.”

He added, “The acquisition also bolsters our ability to leverage Noumed’s established customer relationships and long-term supply contracts. Backed by Noumed’s strong regulatory capabilities, SAI Parenteral will further expand its footprint in regulated markets, thereby enhancing both revenue quality and visibility.”

Mr. Mark Thulborne, Managing Director, Noumed Pharmaceuticals Pty Ltd, stated: “We are delighted to formalise this strategic partnership. Having collaborated with SAI Parenteral for a considerable period, we are confident that together we can accelerate our product pipeline, leverage SAI’s manufacturing strengths, and address growing demand in Australia, New Zealand, and global markets. This alliance positions both companies to create substantial long-term value for all stakeholders.”

SAI Parenteral Limited is backed by marquee investors including Samarsh Capital, Vyom Partners, Blue Lotus Capital, and Gruhas.